Georges Gemayel is Director at SUPERNUS PHARMACEUTICALS, INC. (SUPN). They have made 8 open-market trades across 3 companies since 2006, most recently 2026-03-06.
CIK 0001256088
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
1 open-market purchase totalling $169K since 2006, against 7 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| SUPN | 36,064 | $1.4M |
| MNTA | 24,090 | $1.3M |
| ADLR | 82,406 | — |
| GENZ | 46,535 | — |
| NPSP | 15,188 | — |
| RPTP | 8,330 | — |
| Total | $2.6M |
Shares reported on the most recent Form 4, priced at the 2026-03-09 close. 4 holdings could not be priced and are excluded from the total.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| SUPN | SELL | 2026-03-05 | 2026-03-09 | $53.38 | $1.0M | -10.0% | -4.9% | -18.1% |
| SUPN | SELL | 2024-11-08 | 2024-11-12 | $36.30 | $783K | -4.5% | -4.7% | -0.0% |
| SUPN | SELL | 2024-11-07 | 2024-11-08 | $36.62 | $1.0M | -2.2% | -0.7% | +5.2% |
| SUPN | SELL | 2024-09-13 | 2024-09-17 | $31.33 | $557K | -2.8% | +7.0% | +15.3% |
| MNTA | SELL | 2020-08-05 | 2020-08-07 | $33.00 | $330K | +61.1% | +61.2% | N/A |
| MNTA | SELL | 2020-07-29 | 2020-07-30 | $30.00 | $300K | -6.8% | +74.2% | N/A |
| NPSP | SELL · 10b5-1 | 2014-02-13 | 2014-02-14 | $37.70 | $233K | N/A | N/A | N/A |
| GENZ | SELL | 2007-10-30 | 2007-11-02 | $76.00 | $2.9M | N/A | N/A | N/A |
| GENZ | BUY | 2006-05-11 | 2006-06-16 | $56.47 | $169K | N/A | N/A | N/A |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.